Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
JCAR018
i
Other names:
JCAR018, anti-CD22 chimeric antigen receptor T-cells, T-cell chimeric antigen receptor cellular therapy targeting CD-22, CD22-CAR, JCAR-018, JCAR 018, anti-CD22-human scFv CAR T cell therapy
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
BMS, National Cancer Institute
Drug class:
CD22-targeted CAR-T immunotherapy
Related drugs:
‹
CAR-T19/CAR-T22 immunotherapy (1)
4SCAR-CD22/CD123/CD38/CD10/CD20/TSLPR (0)
4SCAR-T (0)
AUTO1/22 (0)
AUTO3 (0)
Anti-CD19/CD20/CD22 CAR T-Cells (0)
Anti-CD22 CAR-T Cells (0)
CAR-T CD19/CD20/CD22/CD30 (0)
CAR20.19.22 T (0)
CART-19/22 (0)
CART22 (0)
CART22 (0)
CD19 and CD22 targeted prime CAR-T (0)
CD19-CD22 CAR-T (0)
CD19/CD22 CAR T-cells (0)
CD19/CD22 CAR-T cell therapy (0)
CD19/CD22 chimeric antigen receptor T cell (0)
CD19/CD22 dual-target CAR-T (0)
CD19x22 CAR T (0)
CD22-CART (0)
CD22-targeted CAR-T cell therapy (0)
CD22/CD19 CAR T (0)
CT120 (0)
CTA101 (0)
GC022F (0)
HY004 (0)
IMJ995 (0)
LB1909 (0)
LCAR-AIO (0)
MB-CAR-T19-22 (0)
SCRI-CAR19x22v2 (0)
SCRI-CAR22v2 (0)
Senl_22 (0)
Senl_H19x22P (0)
ThisCART22 (0)
UCART20x22 (0)
UCART22 (0)
anti-CD19/CD22 CAR-T cells (0)
anti-CD22 CAR T (0)
anti-CD22 CAR-T cell therapy (0)
anti-CD22 CAR-T therapy (0)
anti-CD22-CAR (0)
autologous TriCAR T (0)
CRG-022 (0)
multi-CAR-T cell therapy (0)
multi-target gene-modified CAR-T/TCR-T cell immunotherapy (0)
sequential different B cell antigen-targeted CAR T-cell therapy (0)
CAR-T19/CAR-T22 immunotherapy (1)
4SCAR-CD22/CD123/CD38/CD10/CD20/TSLPR (0)
4SCAR-T (0)
AUTO1/22 (0)
AUTO3 (0)
Anti-CD19/CD20/CD22 CAR T-Cells (0)
Anti-CD22 CAR-T Cells (0)
CAR-T CD19/CD20/CD22/CD30 (0)
CAR20.19.22 T (0)
CART-19/22 (0)
CART22 (0)
CART22 (0)
CD19 and CD22 targeted prime CAR-T (0)
CD19-CD22 CAR-T (0)
CD19/CD22 CAR T-cells (0)
CD19/CD22 CAR-T cell therapy (0)
CD19/CD22 chimeric antigen receptor T cell (0)
CD19/CD22 dual-target CAR-T (0)
CD19x22 CAR T (0)
CD22-CART (0)
CD22-targeted CAR-T cell therapy (0)
CD22/CD19 CAR T (0)
CT120 (0)
CTA101 (0)
GC022F (0)
HY004 (0)
IMJ995 (0)
LB1909 (0)
LCAR-AIO (0)
MB-CAR-T19-22 (0)
SCRI-CAR19x22v2 (0)
SCRI-CAR22v2 (0)
Senl_22 (0)
Senl_H19x22P (0)
ThisCART22 (0)
UCART20x22 (0)
UCART22 (0)
anti-CD19/CD22 CAR-T cells (0)
anti-CD22 CAR T (0)
anti-CD22 CAR-T cell therapy (0)
anti-CD22 CAR-T therapy (0)
anti-CD22-CAR (0)
autologous TriCAR T (0)
CRG-022 (0)
multi-CAR-T cell therapy (0)
multi-target gene-modified CAR-T/TCR-T cell immunotherapy (0)
sequential different B cell antigen-targeted CAR T-cell therapy (0)
›
Associations
News
Trials
Filter by
Latest
18d
Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies (clinicaltrials.gov)
P1, N=133, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed | Trial completion date: Jun 2040 --> Oct 2024
18 days ago
Trial completion • Trial completion date
|
CD22 (CD22 Molecule)
|
CD22 expression
|
JCAR018 • anti-CD22 CAR T
10ms
Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies (clinicaltrials.gov)
P1, N=123, Active, not recruiting, National Cancer Institute (NCI) | Suspended --> Active, not recruiting
10 months ago
Enrollment closed
|
CD22 (CD22 Molecule)
|
CD22 expression
|
JCAR018 • anti-CD22 CAR T
1year
Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies (clinicaltrials.gov)
P1, N=123, Suspended, National Cancer Institute (NCI) | N=208 --> 123 | Recruiting --> Suspended
1 year ago
Enrollment change • Trial suspension
|
CD22 (CD22 Molecule)
|
CD22 expression
|
JCAR018 • anti-CD22 CAR T
over2years
Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant (clinicaltrials.gov)
P1, N=23, Recruiting, National Cancer Institute (NCI) | Not yet recruiting --> Recruiting
over 2 years ago
Enrollment open
|
CD22 (CD22 Molecule)
|
cyclophosphamide • JCAR018
over3years
Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies (clinicaltrials.gov)
P1, N=208, Recruiting, National Cancer Institute (NCI) | N=126 --> 208
over 3 years ago
Clinical • Enrollment change
|
CD22 (CD22 Molecule)
|
JCAR018
over3years
Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant (clinicaltrials.gov)
P1, N=23, Not yet recruiting, National Cancer Institute (NCI)
over 3 years ago
Clinical • New P1 trial • IO biomarker
|
CD22 (CD22 Molecule)
|
JCAR018
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login